Search research articles
Contact Us
Filters
Showing results (81-90 of 250) with videos related to
Page
of 25
Sort By:
Blood
|
May 23, 2019
Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma
Ajai Chari, Joaquín Martinez-Lopez, María-Victoria Mateos, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 21, 2019
Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Siltuximab in High-Risk Smoldering Multiple Myeloma
Timothy A Brighton, Amit Khot, Simon J Harrison, et al.
The Lancet. Oncology
|
December 6, 2021
Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study
Saad Z Usmani, Hang Quach, Maria-Victoria Mateos, et al.
Haematologica
|
July 20, 2004
Feasibility and results of autologous stem cell transplantation in de novo acute myeloid leukemia in patients over 60 years old. Results of the CETLAM AML-99 protocol
Albert Oriol, Josep-Maria Ribera, Jordi Esteve, et al.
American Journal of Hematology
|
September 20, 2025
Optical Genome Mapping (OGM): Validation and Clinical Utility in the Cytogenetic Diagnosis of Multiple Myeloma
Adela Cisneros, Mar Mallo, Aleix Méndez-López, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 13, 2012
Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia
Hagop M Kantarjian, Xavier G Thomas, Anna Dmoszynska, et al.
Blood Advances
|
December 7, 2020
Quantitative expression of Ikaros, IRF4, and PSMD10 proteins predicts survival in VRD-treated patients with multiple myeloma
Irena Misiewicz-Krzeminska, Cristina de Ramón, Luis A Corchete, et al.
International Journal of Hematology
|
March 2, 2011
Lenalidomide is effective as salvage therapy in refractory or relapsed multiple myeloma: analysis of the Spanish Compassionate Use Registry in advanced patients
Adrián Alegre, Beatriz Aguado, Pilar Giraldo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 6, 2020
Ixazomib as Postinduction Maintenance for Patients With Newly Diagnosed Multiple Myeloma Not Undergoing Autologous Stem Cell Transplantation: The Phase III TOURMALINE-MM4 Trial
Meletios A Dimopoulos, Ivan Špička, Hang Quach, et al.
European Journal of Haematology
|
February 6, 2019
Pomalidomide-dexamethasone for treatment of soft-tissue plasmacytomas in patients with relapsed / refractory multiple myeloma
Raquel Jiménez-Segura, Miquel Granell, Mercè Gironella, et al.
Page
of 25
Search research articles
Search
Showing results (81-90 of 250) with videos related to
Sort By:
Page
of 25
Blood
|
May 23, 2019
Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma
Ajai Chari, Joaquín Martinez-Lopez, María-Victoria Mateos, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 21, 2019
Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Siltuximab in High-Risk Smoldering Multiple Myeloma
Timothy A Brighton, Amit Khot, Simon J Harrison, et al.
The Lancet. Oncology
|
December 6, 2021
Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study
Saad Z Usmani, Hang Quach, Maria-Victoria Mateos, et al.
Haematologica
|
July 20, 2004
Feasibility and results of autologous stem cell transplantation in de novo acute myeloid leukemia in patients over 60 years old. Results of the CETLAM AML-99 protocol
Albert Oriol, Josep-Maria Ribera, Jordi Esteve, et al.
American Journal of Hematology
|
September 20, 2025
Optical Genome Mapping (OGM): Validation and Clinical Utility in the Cytogenetic Diagnosis of Multiple Myeloma
Adela Cisneros, Mar Mallo, Aleix Méndez-López, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 13, 2012
Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia
Hagop M Kantarjian, Xavier G Thomas, Anna Dmoszynska, et al.
Blood Advances
|
December 7, 2020
Quantitative expression of Ikaros, IRF4, and PSMD10 proteins predicts survival in VRD-treated patients with multiple myeloma
Irena Misiewicz-Krzeminska, Cristina de Ramón, Luis A Corchete, et al.
International Journal of Hematology
|
March 2, 2011
Lenalidomide is effective as salvage therapy in refractory or relapsed multiple myeloma: analysis of the Spanish Compassionate Use Registry in advanced patients
Adrián Alegre, Beatriz Aguado, Pilar Giraldo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 6, 2020
Ixazomib as Postinduction Maintenance for Patients With Newly Diagnosed Multiple Myeloma Not Undergoing Autologous Stem Cell Transplantation: The Phase III TOURMALINE-MM4 Trial
Meletios A Dimopoulos, Ivan Špička, Hang Quach, et al.
European Journal of Haematology
|
February 6, 2019
Pomalidomide-dexamethasone for treatment of soft-tissue plasmacytomas in patients with relapsed / refractory multiple myeloma
Raquel Jiménez-Segura, Miquel Granell, Mercè Gironella, et al.
Page
of 25